Table_1_Expression of TIMPs and MMPs in Ovarian Tumors, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Trea... حسب Ruth M. Escalona (9466739)

Supplemental Figure S1 from Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model حسب Eva Tonsing-Carter (7039142)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer حسب Min Wei (16918572)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer حسب Min Wei (16918572)

Image_4_Potent in vivo efficacy of oral gallium maltolate in treatment-resistant glioblastoma.jpeg حسب Mona M. Al-Gizawiy (17787488)

"…Background<p>Treatment-resistant glioblastoma (trGBM) is an aggressive brain tumor with a dismal prognosis, underscoring the need for better treatment options. …"

Image_6_Potent in vivo efficacy of oral gallium maltolate in treatment-resistant glioblastoma.jpeg حسب Mona M. Al-Gizawiy (17787488)

"…Background<p>Treatment-resistant glioblastoma (trGBM) is an aggressive brain tumor with a dismal prognosis, underscoring the need for better treatment options. …"

Image_1_Potent in vivo efficacy of oral gallium maltolate in treatment-resistant glioblastoma.jpeg حسب Mona M. Al-Gizawiy (17787488)

"…Background<p>Treatment-resistant glioblastoma (trGBM) is an aggressive brain tumor with a dismal prognosis, underscoring the need for better treatment options. …"

Image_5_Potent in vivo efficacy of oral gallium maltolate in treatment-resistant glioblastoma.jpeg حسب Mona M. Al-Gizawiy (17787488)

"…Background<p>Treatment-resistant glioblastoma (trGBM) is an aggressive brain tumor with a dismal prognosis, underscoring the need for better treatment options. …"

Image_2_Potent in vivo efficacy of oral gallium maltolate in treatment-resistant glioblastoma.jpeg حسب Mona M. Al-Gizawiy (17787488)

"…Background<p>Treatment-resistant glioblastoma (trGBM) is an aggressive brain tumor with a dismal prognosis, underscoring the need for better treatment options. …"

Image_3_Potent in vivo efficacy of oral gallium maltolate in treatment-resistant glioblastoma.jpeg حسب Mona M. Al-Gizawiy (17787488)

"…Background<p>Treatment-resistant glioblastoma (trGBM) is an aggressive brain tumor with a dismal prognosis, underscoring the need for better treatment options. …"

Supplementary Material for: Cancer associated fibroblasts induce proliferation and therapeutic resistance to everolimus in neuroendocrine tumors through STAT3 activation حسب Amin T. (14226773)

"…Introduction Cancer-associated fibroblasts (CAF) have been identified as relevant contributors to cancer progression and drug resistance in many tumors. Although neuroendo-crine tumors (NET) are often associated with a strong stromal reaction, no study has addressed whether CAF are involved in progression and therapeutic resistance in NET. …"

MET knockdown decreases MET expression and activation. حسب Karolin Ebert (7434713)

Supplemental Figure 7 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume حسب Nicholas Theodosakis (3466673)

Supplemental Figure 2 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume حسب Nicholas Theodosakis (3466673)

Supplemental Table 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume حسب Nicholas Theodosakis (3466673)

Supplemental Figure 6 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume حسب Nicholas Theodosakis (3466673)

Supplemental Figure 4 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume حسب Nicholas Theodosakis (3466673)

Supplemental Figure 8 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume حسب Nicholas Theodosakis (3466673)

Supplemental Figure 5 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume حسب Nicholas Theodosakis (3466673)

Supplemental Figure 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume حسب Nicholas Theodosakis (3466673)